Background: Diabetes is associated with an increased risk of major adverse cardiac events (MACE) following percutaneous coronary intervention.
Background: Neointimal growth patterns of new generation drug-eluting stents are not yet fully elucidated. We developed a new visualization method and compared neointimal growth patterns between biodegradable polymer biolimus-eluting stent (BES) and permanent polymer everolimus-eluting stent (EES) using optical coherence tomography (OCT).
Background: Neointimal growth patterns of new generation drug-eluting stents are not yet fully elucidated. We developed a new visualization method and compared neointimal growth patterns between biodegradable polymer biolimus-eluting stent (BES) and permanent polymer everolimus-eluting stent (EES) using optical coherence tomography (OCT).
Background: Biodegradable polymer drug eluting stents improve safety and efficacy when compared to durable polymer drug eluting stents, but this may not be true in diabetic patients.
Background: Nobori stent (Terumo Co., Tokyo Japan), is the new concept Drug Eluting Stent which has unique bioabsorbable polymer (Poly-Lactic Acid) and the anti-proliferative agent Biolimus A9. We investigated the safety and the efficacy of Nobori stent comparing to Cypher stent in Japanese population by a single blinded 3:2 randomized trial and met the primary endpoint, non inferiority in TVF. This is the first report of three year clinical follow up data of Nobori Biolimus Eluting stent compared to Cypher Sirolimus Eluting stent in Japanese population.
Background: With the introduction of drug eluting stents (DES) in this decade, treatment of patients with STEMI with these devices has emerged as a rational PCI alternative. In spite of the unquestionable benefits of DES in terms of reduction of restenosis and TVR, specific concerns have arisen with regard to their short- and long-term safety. We aim to assess short- and long-term outcomes in STEMI patients treated with Nobori, DES with biodegradable polymer.
Background: The role of percutaneous coronary intervention (PCI) in the treatment of multivessel coronary artery disease (CAD) is still controversial and widely discussed. More liberal use of drug-eluting stents (DES) increased proportion of those patients undergoing PCI procedure, raising a need for more clinical evidence. The recent reported COMPARE II trial showed similar results of Biolimus-eluting Nobori stent (BES) and Everolimus-eluting Xience/Promus stent (EES) at 1-year in an all comers population. We aim to compare safety and efficacy outcomes in patients with multivessel CAD (a pre-specified study subset) treated with BES and EES in COMPARE II trial.
Background: The newer generation drug eluting stents (DES) have shown advantages over first generation DES, particularly relating to long term safety. However, comparative data for contemporary DES are still insufficient. We aim to compare safety and efficacy between Nobori DES, eluting Biolimus A9 from an abluminal biodegradable polymer (BES) and Xience/Promus DES eluting everolimus from a permanent polymer (EES)
Background: Treatment of long lesions (LL) remains a challenge in interventional cardiology, with a high propensity to restenosis. Our aim was to evaluate the clinical outcomes of the patients with LL treated with a Nobori biolimus eluting stent (BES) versus patients treated with an everolimus eluting stent (EES) in a real world / all-comer situation as an substudy of COMPARE II trial.
Background: Small coronary vessels (reference diameter <2.75mm) are often associated with diabetic and female patients and remain an important challenge in interventional cardiology. We performed a pre-specified substudy on outcome in patients with small vessel treatment within the all-comer COMPARE II trial.
Background: Small coronary vessels (reference diameter <2.75mm) are often associated with diabetic and female patients and remain an important challenge in interventional cardiology. We performed a pre-specified substudy on outcome in patients with small vessel treatment within the all-comer COMPARE II trial.
Aims: The specific benefits of biolimus-eluting stents (BES) with a biodegradable polymer have been recently demonstrated during the long term follow-up of the LEADERS all-comers randomised trial. It is thus of interest to determine whether the long-term follow-up of patients treated with the BioMatrix™ stent system in routine clinical practice is associated with a similarly low rate of late adverse events. We present the 2-year results of the 1123 patient e-BioMatrix Post Market Surveillance (PMS) registry, and focus on the safety and efficacy of the stent in the very late phase (>1 year) by performing a landmark analysis according to a pre-specified 12 months time-point.
Aims: New generation drug-eluting stents, biolimus-eluting stents (BES), and everolimus-eluting stents (EES), are expected to provide minimal inflammatory reaction and good neointimal coverage. However, there is no data regarding vessel response in the very early period after BES and EES implantation. The aim of this study was to assess detailed response at 1-month after BES and EES implantation using optical coherence tomography (OCT).
Aims: The aim of DIVERGE trial is to evaluate the safety and performance of the Axxess™ stent system for the treatment of de novo bifurcation lesions in native coronary arteries.
Aims: Compared with bare metal stents (BMS), early generation drug-eluting stents (DES) reduce the risk of revascularisation in patients with ST-elevation myocardial infarction (STEMI) at the expense of an increased risk of very late stent thrombosis (ST). Durable polymer coatings for controlled drug release have been identified as a potential trigger for these late adverse events and this has led to the development of newer generation DES with durable and biodegradable polymer surface coatings with improved biocompatibility. In a recent all-comers trial, biolimus-eluting stents with a biodegradable polymer surface coating were found to reduce the risk of very late ST by 80% compared with sirolimus-eluting stents with durable polymer, which also translated into a lower risk of cardiac death and myocardial infarction (MI) beyond one year.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos